Dr. Liat Mintz has founded and headed DiaLean Ltd., a company that develops peptide therapeutics based on novel proteins discovered using proprietary bioinformatics methodologies. Dr. Mintz is also a principal and part of the founding team of Biocceleration Inc., a company that develops bioinformatics tools and provides consulting services for government agencies and pharmaceutical companies.

Dr. Mintz has been a pioneer in the discovery of splice variants and an inventor of more than 50 U.S. and international patents. She established and headed the Bioinformatics Unit at Tel-Aviv University and was a member of the founding team of Compugen Ltd. (NASDQ: CGEN). As head of the genomics research in Compugen, Dr. Mintz established and managed Compugen’s molecular biology lab and bioinformatics unit and was responsible for converting Compugen’s bioinformatics discoveries into biological entities.

Dr. Mintz attended Tel Aviv University, where she received her PhD in Immunology, Masters of Science in Medical Microbiology and Bacteriology, and Bachelors in Biology and Biological Sciences.

Areas of Expertise

  • Biopharma: Diagnostics, therapeutics
  • Drug Discovery Technology: Biomedical research tools, animal models of diseases
  • Therapeutics: cardiovascular, dermatology, diabetes, metabolism, endocrinology, obesity, gastroenterology and digestive disease, immunology, autoimmune and inflammation, musculoskeletal, orthopedics, neurodegenerative, oncology,
  • Software & Applications: life sciences and biomedical